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Abstract
Background: Patients with pancreatic adenocarcinoma frequently present with depression the symp-
toms of which may precede cancer diagnosis, suggesting that the pathophysiology of depression in
pancreatic adenocarcinoma may result from biological changes that are induced by the presence of the
tumour itself. The present study was conducted to test a hypothesized relationship with the kynurenine
pathway, which has been implicated in both depression and tumour-induced immunosuppression.
Methods: 17 patients with pancreatic adenocarcinoma were recruited and completed mood questionnaires
(Functional Assessment of Cancer Therapy -Pancreatic Cancer, Beck Depression Inventory and the Beck
Anxiety Inventory) and blood testing for serum levels of tryptophan, kynurenine, kynurenic acid and quinolinic
acid. Tumour burden was determined from pathology reports (tumour size and nodal involvement).
Results: Findings indicated a negative correlation between mood scores and the plasma kynurenic acid :
tryptophan ratio in plasma, and a positive correlation between tumour burden and plasma kynurenine level.
Conclusions: This study suggests that pancreatic cancer may influence mood via the kynurenine
pathway. The relationship of the kynurenine pathway with pancreatic tumour burden should be explored
further in large multicentre studies because a better understanding of this physiology might have
significant clinical benefit.
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Introduction
Patients with pancreatic adenocarcinoma often present with new-
onset depressive symptoms before they are diagnosed with cancer,
as noted in case reports dating from the 1920s and more recent
systematic studies.1 A 1967 series of 46 patients with pancreatic
cancer found that 76% had depressive symptoms and approxi-
mately half of the depressed patients experienced the onset of
depression prior to the diagnosis of cancer.2 This pattern of psy-
chiatric symptoms is not seen in patients with some other
abdominal neoplasms, such as gastric cancer.3 This onset of
depression prior to cancer diagnosis suggests that the depression
is not just a grief response to a disease with a poor prognosis. Such
findings suggest that the pathophysiology of depression in pan-
creatic cancer may result from biological changes that are induced
by the presence of the tumour itself.1 A deficiency in the neuro-
transmitter serotonin has been linked to major depression; the
closely related kynurenine pathway can shunt tryptophan away
from serotonin synthesis. Additionally, the kynurenine pathway is
implicated in tumour-induced immunosuppression.
The present study was conducted to examine the relationships
amongmood, tumour burden andmetabolites of the indoleamine
2,3-dioxygenase-mediated kynurenine pathway in patients with
pancreatic adenocarcinoma. Indoleamine 2,3-dioxygenase (IDO)
is an enzyme expressed in pancreatic cancer that catalyses the
rate-limiting step in the kynurenine pathway, the conversion of
tryptophan to kynurenine. To the present authors’ knowledge, this
relationship has not been previously studied.
Materials and methods
The study was approved by the Columbia University Institutional
Review Board. Seventeen patients with pancreatic adenocarci-
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noma were enrolled over a 2-year period. Patients with potentially
resectable disease were recruited prior to surgery. The Functional
Assessment of Cancer Therapy–Pancreatic Cancer (FACT-PA),
the Beck Depression Inventory (BDI) and the Beck Anxiety Inven-
tory (BAI) were administered. The FACT-PA is a self-administered
generic (FACT-G) and pancreatic disease-specific (FACT-PA)
health status survey in which participants are scored against age-
and gender-matched control subjects. The scaled measures are
transformed to a scale of 0–100 on which a score of 0 represents
the worst quality of life and a score of 100 represents the best. The
BDI is a self-report measure of depressive symptoms. The instru-
ment is scored on a scale of 0–63 on which higher scores indicate
more severe depression. The BAI is a self-administered measure of
anxiety symptoms. The instrument is scored on a scale of 0–63 on
which higher scores indicate more severe anxiety. These psychiat-
ric instruments have been validated and used in cancer patient
studies.4–6
Upon enrolment, 25 ml of blood was collected from each
patient by venipuncture. Plasma samples were processed and
frozen at −56.7°C. Plasma levels of tryptophan, kynurenine,
kynurenic acid and quinolinic acid were assayed. Tryptophan was
measured using a validated, unpublished liquid chromatographic
procedure that utilizes the native fluorescence of tryptophan for
detection. An internal standard 5-methyltryptophan was added
to the plasma sample (0.25 ml), which was then subjected to
deproteinization and centrifugation. An aliquot of the superna-
tant was injected on a column. Using a phosphate buffer (pH 4.7)
and acetonitrile as the mobile phase with a reversed-phase
octadecylsilane (octadecylsilyl groups) column (4 μm, 3.9 ×
150 mm, Nova-Pak C18; Waters Corp., Milford, MA, USA), tryp-
tophan and the internal standard eluted in < 12 min. Fluorescence
detection was optimized using an excitation wavelength of
290 nm and analysed at 340 nm. The interassay variability of
plasma tryptophan did not exceed 5.1% in the high-quality con-
trols and 7.2% in the low-quality controls (n = 22 samples).
Plasma levels of kynurenine, kynurenic acid and quinolinic acid
were measured using previously described methods.7–9
Tumour burden was determined from surgical pathology
reports. Specifically, tumour burden was assessed according to
the maximal tumour diameter and the percentage of metastatic
lymph nodes in the surgical resection specimen (metastatic
nodes/total nodes in specimen). Only lymph nodes with metasta-
ses were included; lymph nodes found to be positive as a result of
direct invasion by a contiguous primary tumour were excluded.
Patients were excluded if their history included any of the fol-
lowing: treatment within the past month with antidepressant
medications that affect serotonin physiology, including selective
serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine
reuptake inhibitors (SNRIs) and tricyclic antidepressants (TCAs)
(benzodiazepine use was permitted); autoimmune diseases such
as systemic lupus erythematosus (SLE), multiple sclerosis and
rheumatoid arthritis, or congestive heart failure, recent stroke or
other major surgery in the past month.
Data were analysed for normality using the Shapiro–Wilks test.
For variables that did not satisfy the normality assumption, the
non-parametric bivariate rho (Spearman) correlation test was
performed. The effects of multiple correlations on potentially
related variables were corrected for by performing multivariate
partial correlations on variables found to be significant in the
bivariate analysis. For the multivariate partial correlation analysis,
variables that did not satisfy the normality assumption were trans-
formed using the ranks of the values to achieve normality.
Results
Demographic information, mood and pathology scores for the
study population are shown in Table 1. Multiple IDO metabolites
were identified and measured. Median values for metabolites that
proved significant were as follows: tryptophan 47 nm/ml (range:
31–76 nm/ml); kynurenine 2.18 μmol (range: 1.25–3.28 μmol),
and kynurenic acid 100 nmol (range: 38–730 nmol). The median
plasma kynurenic acid : tryptophan ratio (KATR) was 2.2 (range:
0.8–18.3).
A significant negative correlation was found between the BDI
score and plasma KATR (P = 0.008, ρ = −0.617) (Table 2). Thus, a
lower KATR correlated with worse depressive symptoms. In addi-
tion, a significant negative correlation was found between the BAI
score and plasma KATR (P = 0.029, ρ = −0.523), whereby a lower
KATR correlated with worse anxiety (Table 2). In both cases, the
Table 1 Demographics, mood and pathology results in 17 patients
with pancreatic adenocarcinoma
Age, years, median (range) 65 (51–85)
Gender 9 male, 8 female
Race 17 White
BAI score, median (range) 4.2 (0–18)
BDI score, median (range) 7 (0–13.65)
FACT-PA: physical well-being subscore,
median (range)
25 (17–28)
FACT-PA: social well-being subscore,
median (range)
26 (0–28)
FACT-PA: emotional well-being subscore,
median (range)
19 (8–24)
FACT-PA: functional well-being subscore,
median (range)
15 (0–27)
FACT-PA: additional concerns subscore,
median (range)
29 (14–35)
FACT-G: subscore, median (range) 84.5 (48–106)
FACT-PA: total score, median (range) 109 (64–140)
Lymph nodes positive for metastatic
disease, %, median (range)
0 (0–36%)
Diameter of primary tumour, cm,
median (range)
2.9 (0.03–4.6)
BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory; FACT-PA,
Functional Assessment of Cancer Therapy–Pancreatic Cancer; FACT-G,
Functional Assessment of Cancer Therapy–Generic.
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correlation appears to be driven mostly by kynurenic acid; anxiety
may also be a component of a major depressive episode in many
patients.
A significant positive correlation was found between plasma
kynurenine and the percentage of lymph nodes positive for meta-
static disease (P = 0.034, ρ = 0.515), whereby patients with higher
serum kynurenine levels hadmore metastatic disease in the lymph
nodes. There was a significant negative correlation between the
maximal tumour diameter and plasma kynurenine (P = 0.021, ρ =
−0.554). Essentially, a higher plasma kynurenine level correlated
with a smaller primary tumour. Bivariate correlations between
tumour burden and metabolite level are shown in Table 3.
A multivariate partial correlation analysis was performed to
examine the relationship between the significant bivariate corre-
lations (Table 4). The correlations between plasma KATR and
scores on the BDI and BAI remained significant after controlling
for the percentage of positive lymph nodes and maximal primary
tumour diameter.
Discussion
Tryptophan, an essential precursor for serotonin production, is
also a substrate of the kynurenine pathway, which eventually pro-
duces NAD+, as well as several neuroactive byproducts, including
kynurenic acid and quinolinic acid. Interferon-γ (IFN-γ), a
proinflammatory cytokine, upregulates the expression of the
enzyme IDO, which catalyses the conversion of tryptophan to
kynurenine. Thus, in the presence of IFN-γ and subsequent
overexpression of IDO, tryptophan is shunted away from seroto-
nin production toward the kynurenine pathway, leading to
increased levels of neuroactive products of kynurenine metabo-
lism, and less serotonin, which may contribute to symptoms of
depression.10,11
Previous studies of depression have noted that patients with
lower levels of kynurenic acid exhibit more depressive symptoms.
Specifically, it appears that the ratio of kynurenic acid relative to
other metabolites, rather than the absolute level of kynurenic acid,
Table 2 Bivariate (Spearman ρ) correlations between mood score and metabolite level in 17 patients with pancreatic adenocarcinoma
Correlation with BAI score Correlation with BDI score
Tryptophan P = 0.479 P = 0.151
Kynurenine P = 0.493 P = 0.356
Kynurenic acid P = 0.060 P = 0.059
Quinolinic acid P = 0.910 P = 0.914
Tryptophan : kynurenine ratio P = 0.933 P = 0.598
Kynurenic acid : tryptophan ratio P = 0.029, ρ = −0.523 P = 0.008, ρ = −0.617
Quinolinic acid : tryptophan ratio P = 0.811 P = 0.493
BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory.








Tryptophan P = 0.567 P = 0.327
Kynurenine P = 0.021, ρ = −0.554 P = 0.034, ρ = 0.515
Kynurenic acid P = 0.970 P = 0.347
Quinolinic acid P = 0.047 P = 0.339
Tryptophan : kynurenine ratio P = 0.083 P = 0.796
Kynurenic acid : tryptophan ratio P = 0.779 P = 0.800
Quinolinic acid : tryptophan ratio P = 0.132 P = 0.915
Table 4 Partial correlations: mood score and metabolite level when controlling for tumour burden in 17 patients with pancreatic
adenocarcinoma
Control variable Correlation with BDI score Correlation with BAI score
Percentage of lymph nodes positive Kynurenic acid : tryptophan ratio P = 0.002, ρ = −0.711 P = 0.030, ρ = −0.543
Maximum tumour diameter Kynurenic acid : tryptophan ratio P = 0.006, ρ = −0.654 P = 0.350, ρ = −0.528
BDI, Beck Depression Inventory; BAI, Beck Anxiety Inventory.
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determines mood.11 This is consistent with the present finding of
a correlation between worse mood and a lower KATR.
In addition to psychopathological morbidities, IDO expression
and the kynurenine shunt have also been implicated in tumour-
induced immunomodulation. IDO is expressed in a number of
tumours, including pancreatic adenocarcinoma.12,13 The exact
mechanism of IDO-induced immunosuppression remains con-
troversial; some authors propose that enhanced IDO expression
results in immune tolerance to tumour antigens through modifi-
cations of T cell tryptophan catabolism.12–15 Experimentally,
IDO inhibition with the false metabolite 1-methyl-d-tryptophan
(D-1MT) has been shown to limit tumour growth; use of D-1MT
is currently being evaluated in two National Cancer Institute-
sponsored Phase I trials.15 In an immunocompetent state, the
body mounts an inflammatory T cell response against tumour
antigens. However, this inflammatory response exerts a selection
pressure in favour of tumour cells that express IDO and are there-
fore capable of inducing T cell tolerogenicity in the local
microenvironment or in tumour-draining lymph nodes.15 The
present authors hypothesize that, in pancreatic cancer, a side-
effect of enhanced IDO expression is an imbalance in the produc-
tion of neuroactive kynurenine pathway metabolites and that this
may result in symptoms of depression. In animal solid-tumour
models, increased IDO expression in the tumour, measured
directly by immunohistological analysis, appears to correlate with
systemic markers of increased IDO activity, such as kynurenine
pathway byproducts.16
In line with this hypothesis, a positive correlation was found
between kynurenine level and burden of metastatic disease to
the lymph nodes. It might be expected that patients shunting
more tryptophan to the kynurenine pathway would produce
more locally immunosuppressive metabolites with a subsequent
increase in metastatic disease. A negative correlation emerged
between the maximum diameter of the primary lesion and
kynurenine level. The present authors hypothesize that tumours
with greater IDO expression and resultant kynurenine shunting
metastasize earlier when the primary lesion is smaller, compared
with less aggressive tumours with no or lower levels of IDO
expression, although this temporal relationship cannot be dem-
onstrated using the current data.
To date, the present authors are unaware of any published data
exploring the impact of IDO and tryptophan metabolism on psy-
chopathological morbidity in pancreatic cancer patients. This
relationship should be explored in large multicentre studies;
data on patients with other gastrointestinal malignancies would
be useful as control material. Additionally, direct evidence of
IDO metabolite secretion by pancreatic tumours would further
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